Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transfusional Iron Overload
Conditions
Transfusional Iron Overload, Transfusional Hemosiderosis
Trial Timeline
Nov 1, 2007 → Mar 1, 2013
NCT ID
NCT00600938About Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine
Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine is a phase 2 stage product being developed by Novartis for Transfusional Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT00600938. Target conditions include Transfusional Iron Overload, Transfusional Hemosiderosis.
What happened to similar drugs?
1 of 2 similar drugs in Transfusional Iron Overload were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00600938 | Phase 2 | Completed |
Competing Products
6 competing products in Transfusional Iron Overload
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 2 | 35 |
| ICL670 | Novartis | Phase 2 | 35 |
| deferasirox | Novartis | Pre-clinical | 26 |
| Deferasirox | Novartis | Phase 2 | 35 |
| deferasirox: | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 3 | 40 |